Prognosis Factors in Patients With Primary Central Nervous System Lymphoma

PCNSL Clinical Trial

Official title:

Prognosis Factors in Patients With Primary Central Nervous System Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05167630
• Other study ID #: hnslblzlzx20211001
• Status: Recruiting
• Start date: September 1, 2013
• Est. completion date: December 15, 2021

Study information

• Verified date: December 2021
• Source: Zhengzhou University
• Contact: Mingzhi Zhang, Doctor
• Phone: +8637166295561
• Email: mingzhi_zhang1[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Primary central nervous system lymphoma (PCNSL) is a rare extranodal non-hodgkin's lymphoma confined to the central nervous system. It accounts for about 4% of all intracranial tumors and 4% to 6% of all non-Hodgkin's lymphomas . Among them, the most common type is diffuse large B cell lymphoma (DLBCL), accounting for about 95% of all cases. High dose methotrexate (HD-MTX) based chemotherapy can improve the prognosis of patients, but only 30% to 40% of patients can achieve sustained remission, and the overall prognosis is very poor[4, 6]. Currently, the International Extranodal Lymphoma Study Group (IESLG) prognostic scoring system and the Memorial Sloan Kettering Cancer Center (MSKCC) prognostic index are widely used to evaluate the prognosis in patients with PCNSL. However, IESLG model has some limitations such as the relatively small number of patients and short follow-up period. MSKCC model may have an inherent selection bias because retrospective data were collected from a single large institution. Therefore, there is a urgent need to identify novel indicators for prognosis evaluation and risk stratification in PCNSL patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 15, 2021
• Est. primary completion date: December 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

(i)The pathological biopsy and immunohistochemistry diagnosis were PCNSL according to WHO diagnostic criteria for PCNSL in 2016. (ii) No treatment has been received. (iii)There were no diseases with malignant tumor, serious infection, other blood system diseases, immune system diseases and other conditions which may have great influence on peripheral blood lymphocyte count. (iv) The clinical data were complete.

Exclusion Criteria:

-

Related Conditions & MeSH terms

• PCNSL
• Survival Analysis

Intervention

Other:
• prognostic marker
prognostic marker

Locations

Country	Name	City	State
China	Zhengzhou university	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Zhengzhou University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	from the date of diagnosis to death from any cause or to the date of last follow-up	from September 1, 2013 to June 1, 2020